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HCCUbiquitin C-terminal hydrolase 37 (UCH37) plays a crucial role in numerous biological processes and is also
involved in oncogenesis. In this study, clinicopathologic data showed that UCH37 was over-expressed in
hepatocellular carcinoma (HCC) cancerous tissues and was a signiﬁcant predictor for time to recurrence
(TTR). In vitro, we discovered that UCH37 could promote cell migration and invasion. Subsequently, we
utilized Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) to identify differentially expressed pro-
teins in UCH37 over-expressing cells compared with the control cells, and found that PRP19, an essential RNA
splicing factor, was up-regulated. The relationship between UCH37, PRP19 and the capability of cell migration
and invasion was further conﬁrmed. Collectively, this study demonstrated that UCH37 could promote cell mi-
gration and invasion in HCC cell lines through interacting and deubiquitinating PRP19, and suggested that
UCH37 could be a novel predictor for HCC recurrence after curative resection.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common cancer
and the third most common cause of cancer-related mortality in the
world [1]. Its incidence and mortality rates have increased in recent
years [2], and the high rate of recurrence or metastasis after curativecomplex; ACN, acetonitrile; AFP,
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rights reserved.resection remains one major obstacle for further improving the prog-
nosis of HCC patients [3,4]. Several prognostic biomarkers in HCC
have been reported recently [5–7]. Among these, alpha-fetoprotein
(AFP) is still the best marker to supervise the recurrence and
metastasis in AFP-positive HCC patients after operation [8]. Never-
theless, it is still difﬁcult to predict prognosis in early-stage HCC
in the AFP-normal patients [3,9]. Therefore, it is important to deter-
mine molecular signatures that deﬁne the risk of recurrence
and metastatic potential of HCC. And such markers would allow ap-
propriate therapeutic regimens to be applied earlier in the disease
course.
Ubiquitin (Ub), a 76-amino-acid polypeptide, is ubiquitously
distributed and highly conserved throughout eukaryotic organisms.
Over the last few decades, conjugation of Ub and ubiquitin-like
proteins to intracellular proteins has emerged as a critical regulatory
process in virtually all aspects of cell biology [10–12]. Nevertheless, it
is well recognized that protein ubiquitination, like protein phosphor-
ylation, is a highly reversible process that can be regulated in the cell.
Deubiquitinating enzymes (DUBs), capable of removing Ub from pro-
tein substrates, are also involved in numerous biological processes
such as transcriptional regulation, growth and differentiation, and on-
cogenesis [13–15]. The ubiquitin C-terminal hydrolase (UCH), a sub-
family of DUBs, prefers to cleave relatively small protein substrates
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members: UCH-L1, UCH-L3, UCH37, and BRCA1-associated protein-1
(BAP1).
In our preliminary study, total proteins extracted from one human
HCC tissue and one normal liver tissue were separated by two-
dimensional (2D) gel electrophoresis, followed by silver staining.
Among all protein spots analyzed, about 200 protein spots were
found to be signiﬁcantly altered between the cancerous tissue and
the normal tissue. With molecular masses ranging from 25 to 40 kDa
and isoelectric point (pI) between 5 and 6, nine protein spots were
found in the cancerous tissue, but not in the normal tissue (Supple-
mentary Fig. 1A). We presumed that UCH37 (molecular mass:
37 kDa; pI: 5.23) was one of the differentially expressed proteins. Sub-
sequently, UCH37 mRNA expression was detected by real-time PCR in
22 HCC cases to conﬁrm the hypothesis. Consequently, we found that
UCH37 mRNA expression in the cancerous tissue was signiﬁcantly
higher than that in the non-cancerous tissue (Supplementary Fig. 1B).
Meanwhile, we chose one of the HCC tissues and one of the normal
liver tissues for western blotting and found that UCH37 was highly
expressed in the cancerous tissue, but weakly expressed in the adjacent
non-cancerous liver and normal liver tissue (Supplementary Fig. 1C).
These were inspiring ﬁndings and indicated that there was likely rela-
tionship between UCH37 and HCC.
UCH37 is a protein of 329 amino acids, which is well conserved
from fungi to humans [17]. Previous studies have focused on the
deubiquitination mechanism of UCH37. It is responsible for the Ub
isopeptidase activity in the 19S proteasome regulatory complex,
which is different from other UCH members, showing that neither
UCH37 alone nor the UCH37–Adrm1 or UCH37–Adrm1–hRpn2 com-
plexes can hydrolyze Lys48-linked di-ubiquitin efﬁciently; that rather,
their incorporation into the 19S complex is required to enable UCH37
to process large ubiquitin protein conjugates such as di-ubiquitin
[17–19]. Further studies have suggested that UCH37 is associated
with the human Ino80 chromatin-remodeling complex (hINO80) in
the nucleus and can be activated via transient association of 19S regu-
latory particle- or proteasome-bound hRpn13 with hINO80 [20,21]. Al-
though there is growing evidence that UCH enzymes and human
malignancies are closely correlated [22], the biological roles of UCH37
have not been determined.
In the current study, we found out that UCH37 was highly
expressed in HCC cancerous tissues and explored the predictive
value of UCH37 for HCC recurrence after curative resection. Further-
more, we discovered that UCH37 could promote cell migration and
invasion in HCC cell lines through interacting and deubiquitinating
PRP19, an essential RNA splicing factor.
2. Material and methods
2.1. Patients and follow-up
Tumor specimens used in the current study were obtained from
90 HCC patients who underwent curative resection at Liver Cancer In-
stitute, Zhongshan Hospital, Fudan University from October 1, 2006 to
December 31, 2008. The inclusion and exclusion criteria of the pa-
tients included (1) having a distinctive pathologic diagnosis of HCC;
(2) having no anti-cancer treatment before liver resection; (3) having
curative liver resection; (4) having suitable formalin-ﬁxed, parafﬁn-
embedded tissues; and (5) having a complete clinicopathologic and
follow-up data.
Curative resection was deﬁned as: (1) complete resection of all
tumor nodules and the surgical free margin of more than 5 mm by
pathological examination; (2) having no cancerous thrombus found
in the portal vein (main trunk or two major branches), hepatic
veins, or bile duct; and (3) having no extrahepatic metastasis found.
Tumor differentiation was deﬁned according to the Edmondson grad-
ing system. Tumor staging was deﬁned according to the 6th edition oftumor-node-metastasis (TNM) classiﬁcation of Unio Internationale
Contra Cancrum. HCC staging was deﬁned according to the Barcelona
Clinic Liver Cancer (BCLC) staging system. The clinicopathologic char-
acteristics of 90 patients were summarized in Supplementary Table 1.
All patients were followed up every 2 months during the ﬁrst post-
operative year and at least every 3–4 months afterward. Follow-upwas
ﬁnished on March 31, 2011. Most patients died of intrahepatic
recurrence, distal metastasis, or complicated liver cirrhosis. All patients
were monitored prospectively by serum AFP, abdomen ultrasonogra-
phy (US), and chest X-ray every 1–6 months, according to the postop-
erative time. For patients with test results suggestive of recurrence,
computed tomography (CT) and/or magnetic resonance imaging
(MRI) were used to verify whether intrahepatic recurrence and/or dis-
tal metastasis had occurred. A diagnosis of recurrence was based on
typical imaging appearance in CT and/or MRI scan and an elevated
AFP level. Overall survival (OS) was deﬁned as the interval between
surgery and either death or the last observation taken. Time to
recurrence (TTR) was measured from the date of resection until either
detection of recurrent tumor or the last follow-up assessment. The
current study was approved by the Institutional Ethics Committee of
ZhongshanHospital, Fudan University. All patients providedwritten in-
formed consent.
2.2. Cells and reagents
Puriﬁed pcDNA3.1-UCH37 plasmid was obtained as a kind gift from
Professor XingzhongWu (Department of Biochemistry, Shanghai Med-
ical School, Fudan University). L02 and Huh7 cell lines were purchased
from the Type Culture Collection of Chinese Academy of Sciences
(Shanghai, China); supervision anti-rabbit or anti-mouse detection re-
agents (HRP), from Kangwei Biotechnology (Beijing, China); mouse
anti-UCH37 antibody, mouse anti-PRP19 antibody and mouse anti-Ub
antibody, from Santa Cruz Biotechnology (Santa Cruz, CA, USA); rabbit
anti-PRP19 antibody, from Abcam Biotechnology (USA); mouse
anti-Flag and anti-GAPDH antibodies, from Kangwei Biotechnology
(Beijing, China); ECL Western Blotting Substrate System, from Pierce
(Rockford, IL, USA); Lipofectamine 2000 and FITC-AnnexinV/
propidium iodide (PI) cell apoptosis kit, from Invitrogen (USA);
Transwell with 8-μm pore polycarbonate membrane, from Millipore
(USA); crystal violet, from Sigma (St. Louis, USA); Matrigel, from BD
Biosciences (USA); MG132, from Merck (Germany); and cyclohexi-
mide, from Beyotime Biotechnology (Shanghai, China).
2.3. Cell culture and stable transfectants
Respectively, L02 and Huh7 cells were cultured in RPMI medium
1640 (Thermo, USA) and DMEM (Thermo, USA), supplemented with
15% fetal bovine serum (FBS) (GIBCO, Austria) at 37 °C in a humidi-
ﬁed atmosphere containing 5% CO2. The cell line stably expressing
UCH37 was generated by the retroviral infection of L02 cells. The
target sequence for the small hairpin RNA (shRNA) for UCH37 is
5′-CCTGTTAATGGGAGACTGTAT-3′. A retrovirus-expressing shRNA
speciﬁc to UCH37 was infected into Huh7 cells. Brieﬂy, a retroviral
vector containing either human UCH37 cDNA with an N-terminal
Flag-tag or a speciﬁc shRNA, pHCMV-G and pCMV-dR8.9 were co-
transfected into 293 T cells, and the viral supernatants were
collected to infect L02 or Huh7 cells. Monoclonal cells were then se-
lected, cloned, and screened for UCH37 over-expression or down-
regulation.
2.4. Real-time quantitative PCR analysis
The mRNA quantity of speciﬁc genes, calculated using the ΔΔCt
method, was normalized against β-actin. Real-time PCR ampliﬁcation
involved the use of an ABI Prism 7500 sequence detector (Applied
Biosystems) and SYBR reagent (Takara, Japan). All the measurements
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as follows:
UCH37: 5′-GTGGTTCAGGACTCCCGACTT-3′ and 5′-GCTGTCTGG
CGAAACTGTTGT-3′;
PRP19: 5′-AAGGCCATACCAAGAAGGTCACCA-3′ and 5′-ACCGACC
AAATCCTGATAGTGGCA-3′;
β-Actin: 5′-AGCGAGCATCCCCCAAAGTT-3′ and 5′-GGGCACGAA
GGCTCATCATT-3′.
2.5. Western blotting (WB)
The cells were lysed in lysis buffer (20 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, and 1% Triton X-100 with protease inhibi-
tor), and their extracts were clariﬁed via centrifugation. The
cell-lysated proteins were separated on 12% SDS-PAGE gel and then
transferred to nitrocellulose membrane (Amersham Biosciences,
Piscataway, NJ). The membranes were blocked in blocking solution
[50 mM Tri–HCl, 150 mM NaCl, 5% (w/v) non-fat dry milk and 0.1%
Tween-20] at room temperature for 1 h, followed by incubation with
appropriate primary antibodies at 4 °C overnight. After incubating
with appropriate secondary antibodies at room temperature for 1 h,
the blots were demonstrated by enzyme-linked chemiluminescence
performed using a LAS3000 imaging system (FUJI, Japan).
2.6. Co-immunoprecipitation (co-IP)
The cell-lysated proteins were precleared with 2 μg appropriate
antibodies at 4 °C for 8 h, and then incubated with protein
A-agarose (Roche) and antibodies at 4 °C overnight. For co-IP exper-
iments using anti-Ub antibody, the cell lysates contained 1% SDS
and received prior heat treatment. The precipitates were pelleted,
washed three times with the lysis buffer and analyzed by western
blotting.
2.7. Immunohistochemistry
Five-micron thick sections of formalin-ﬁxed and parafﬁn-
embedded tissues were deparafﬁnized and rehydrated, followed by
high-temperature antigen retrieval via microwave in 0.1 M citrate so-
lution (pH 6.0) for 15 min. After blocked in 5% normal goat serum at
room temperature for 30 min, the sections were incubated with the
mouse anti-UCH37 antibody at 4 °C overnight, then incubated with
biotinylated secondary antibody at room temperature for 30 min,
and ﬁnally immunostained by the avidin–biotin complex (ABC) tech-
nique using 3,3′-diaminobenzidine (DAB). Hematoxylin was used as a
counterstain.
The interpretation of immunoreactivity was performed in a
semi-quantitative manner by analyzing the extent and intensity of
staining positivity of cells. Interpretation scores were as follows: 0,
≤5% cell positivity or negative staining; +1, 6%–20% cell positivity
or mild staining; +2, 21%–50% cell positivity or moderate staining;
and +3, ≥50% cell positivity or intense staining. Final scores, product
of the scores mentioned earlier, greater than 2 were considered pos-
itive. Staining was evaluated independently by two pathologists and
any discrepancy was resolved by consensus review.
2.8. Immunoﬂuorescence staining and confocal laser scanning microscopy
At the conﬂuence by 60%, the cells were plated onto sterilized
glass coverslips, which were to be washed in phosphate-buffered sa-
line (PBS) and ﬁxed in acetone/carbinol (V/V=1/1) on ice for 2 min.
The slides were then blocked in PBS plus 5% FBS at 37 °C for 1 h,
followed by an incubation with anti-UCH37/anti-Flag and anti-
PRP19 antibodies at 4 °C overnight. After that, the slides were washedthree times with PBS-T (PBS plus 0.2% Triton X-100). For double
immunoﬂuorescence staining, the slides were incubated with
rhodamine-conjugated anti-mouse IgG and ﬂuorescein isothiocya-
nate (FITC)-conjugated anti-rabbit IgG at 37 °C for 1 h. The slides
were then stained brieﬂy with DAPI, washed with PBS-T, mounted,
and analyzed via the confocal laser scanning microscope (Leica TCS
SP5, Germany).
2.9. In vitro cell apoptosis assay
UCH37 overexpressing/silencing cells and the control cells were
stained with FITC-AnnexinV and PI, and then evaluated for apoptosis
by ﬂow cytometry according to the manufacturer's protocol (Invitrogen,
USA). Brieﬂy, cells were harvested after the incubation period, washed
twice in cold PBS, and centrifuged at 1000 rpm for 5 min. About 1×106
cells were re-suspended in 100 μl 1× annexin-binding buffer and trans-
ferred to a sterile ﬂow cytometry glass tube. 5 μl FITC-AnnexinV and
1 μl 100 μg/ml PI were added to each tube, followed by incubation at
room temperature for 15 min in the dark. After the incubation period,
400 μl 1× annexin-binding buffer was added to each tube and samples
were analyzed by ﬂow cytometry (Epics Altra, Beckman, USA).
2.10. In vitro cell cycle distribution assay
UCH37 overexpressing/silencing cells and the control cells were
harvested, washed twice in cold PBS, and then ﬁxed in 70% ethanol
at 4 °C overnight. After centrifugation, the cell pellets were
re-suspended in 1 ml PBS with 100 μg/ml RNase A, 50 μg/ml PI and
0.2% Triton X-100, followed by incubation at 4 °C for 30 min in the
dark. After that, cell cycle distribution was analyzed by ﬂow cytome-
try (Epics Altra, Beckman, USA).
2.11. Scratch-wound assay
Cells were seeded in six-well dishes at a density of 5×105 cells per
well and grown to be conﬂuent. The cell monolayers were scraped
with a sterile blue micropipette tip to create a denuded area of con-
stant width. Cells were washed with PBS to remove cell debris, and
then cultured in medium with 15% FBS. The wound closure was mon-
itored and photographed at 48 h after wounding.
2.12. Transwell migration and invasion assays
Cells were harvested and suspended in the serum free medium
supplemented with 1% BSA. For transwell migration assays, cell sus-
pensions were loaded into the top chamber with a non-coated mem-
brane at a concentration of 2×104 cells/100 μl. For transwell invasion
assays, cell suspensions were loaded into the top chamber with a
Matrigel-coated membrane at a concentration of 1×105 cells/100 μl.
In both assays, medium containing 15% FBS was used as a
chemoattractant in the lower chamber. After incubation for 48 h,
cells that had migrated or invaded to the lower surface of the ﬁlter
were ﬁxed with 4% paraformaldehyde, followed by stained with
0.1% crystal violet. Cells were counted in four independent ﬁelds
with light microscope.
2.13. RNA interference
At the conﬂuence by 70%, the L02-UCH37 cells were transfected
with either PRP19 small interfering RNA (siRNA) or control siRNA
using Lipofectamine 2000 according to the manufacturer's instruc-
tions (Invitrogen, USA). Final concentration of siRNA when added to
the cells was 40 nM. The expression of PRP19 was assessed by immu-
noblotting after transfection. At 48 h post-transfection, cells were
used for scratch-wound assay, or harvested for transwell migration
and invasion assays. The siRNA duplex oligoribonucleotides were
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sequences were as follows:
PRP19 siRNA-1: 5′-GGCUCAUCGAGAAGUACAUTT-3′ (sense) and
5′-AUGUACUUCUCGAUGAGCCTT-3′ (anti-sense);
PRP19 siRNA-2: 5′-GCCACUAUCAGGAUUUGGUTT-3′ (sense) and
5′-ACCAAAUCCUGAUAGUGGCTT-3′ (anti-sense);
PRP19 siRNA-3: 5′-GCCAAGUUCAUCGCUUCAATT-3′ (sense) and
5′-UUGAAGCGAUGAACUUGGCTT-3′ (anti-sense);
Control: 5′-UUCUCCGAACGUGUCACGUTT-3′ (sense) and 5′-ACGU
GACACGUUCGGAGAATT-3′ (anti-sense).
2.14. Protein extraction and preparation for Isobaric Tag for Relative and
Absolute Quantitation (iTRAQ)
The cells were lysed in lysis buffer (20 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, and 1% Triton X-100 with protease inhib-
itor) and sonicated, and the supernatant was collected by centrifuga-
tion at 30,000 g for 15 min. After treated with acetone, the cell extracts
were resuspended in 250 mM triethylammonium bicarbonate (TEAB),
followed by incubation with 10 mM DL-dithiothreitol (DTT) in waterFig. 1. Typical patterns of UCH37 staining in HCC tissues and para-cancerous tissues. (A an
tissue, moderate staining; (D and H) HCC tissue, intense staining; (I and M) para-cancero
para-cancerous tissue, moderate staining; and (L and P) para-cancerous tissue, intense staibath at 56 °C for 1 h, and thenwith 55 mM iodoacetamide (IAM) in dark-
room at room temperature for 45 min. The proteins (100 μg each) were
digested with trypsin at 37 °C for 16 h. Subsequently, the peptides were
dried with vacuum centrifuge and resuspended in 500 mMTEAB for fur-
ther iTRAQ labeling. The protein concentration was determined using
Bradford assay.2.15. iTRAQ labeling and strong cation exchange (SCX) separation
The iTRAQ labeling of tryptic peptides was performed using iTRAQ
reagent Multiplex kit (Applied Biosystems, Foster City, CA) according
to the manufacturer's protocol. The peptides labeled with respective
isobaric tags were incubated at room temperature for 2 h and vacu-
um centrifuged to dryness. Then the iTRAQ labeled peptides samples
were reconstituted in Buffer A [25 mM NaH2PO4, 25% acetonitrile
(ACN), pH 2.7] and fractionated using Ultremex SCX column
(250×4.6 mm, 5 μm particle size, 200 Å pore size) via LC-20AB
HPLC Pump system (Shimadzu, Japan) at ﬂow rate 1.0 ml/min. The
35 min HPLC gradient consisted of 100% Buffer A for 10 min; 5–35%
Buffer B (25 mM NaH2PO4, 25% ACN, 1 M KCl, pH 2.7) for 11 min;
35–80% Buffer B for 1 min; 80% Buffer B for 3 min and 100% Bufferd E) HCC tissue, negative staining; (B and F) HCC tissue, mild staining; (C and G) HCC
us tissue, negative staining; (J and N) para-cancerous tissue, mild staining; (K and O)
ning. The magniﬁcation was 200 (A–D, I–L) and 400 (E–H, M–P).
Table 1
Univariate analyses of factors associated with survival and recurrence.
Variables OS TTR
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Sex (male vs. female) 1.423 (0.606–3.346) 0.418 1.025 (0.505–2.084) 0.945
Age, y (>52 vs. ≤52) 1.034 (0.592–1.804) 0.906 0.895 (0.539–1.487) 0.670
HBsAg (negative vs. positive) 0.915 (0.362–2.312) 0.851 0.651 (0.294–1.440) 0.289
HCV (positive vs. negative) 1.039 (0.142–7.583) 0.970 2.001 (0.486–8.241) 0.337
BCLC stage (stage B/C vs. A) 4.337 (1.557–12.086) 0.005 1.796 (0.933–3.459) 0.080
Liver cirrhosis (yes vs. no) 1.813 (0.563–5.840) 0.319 2.195 (0.795–6.062) 0.129
ALT, units/L (>75 vs. ≤75) 1.295 (0.608–2.761) 0.502 1.303 (0.658–2.578) 0.448
AFP, ng/mL (>20 vs. ≤20) 2.148 (1.180–3.910) 0.012 1.464 (0.873–2.454) 0.149
Tumor differentiation (III–IV vs. I–II) 0.848 (0.264–2.731) 0.783 1.409 (0.563–3.524) 0.464
Tumor encapsulation (complete vs. none) 0.633 (0.341–1.176) 0.148 0.516 (0.291–0.914) 0.023
Tumor size, cm (>5 vs. ≤5) 2.506 (1.279–4.912) 0.007 1.841 (1.058–3.204) 0.031
Tumor number (multiple vs. single) 0.998 (0.521–1.913) 0.996 1.041 (0.573–1.893) 0.894
TNM stage (II–III vs. I) 2.184 (1.225–3.892) 0.008 1.984 (1.187–3.317) 0.009
Vascular invasion (yes vs. no) 2.471 (1.411–4.328) 0.002 2.196 (1.318–3.659) 0.003
UCH37HCC–para-HCC (≥2 vs. b2)a 1.661 (0.941–2.931) 0.080 2.087 (1.232–3.536) 0.006
Bold items have been considered statistically signiﬁcant.
Note: Cox proportional hazards regression model was used in univariate analysis.
Abbreviations: 95% CI, 95% conﬁdence interval; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; and ALT, alanine aminotransferase.
a UCH37HCC–para-HCC: The extra part from the score of the HCC tissue minus that of the para-cancerous tissue, according to the criterion for immunohistochemistry.
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ed fractions were desalted using Strata X C18 column (Phenomenex),
vacuum centrifuged and reconstituted in 0.1% formic acid (FA) for subse-
quent LC–MS/MS analysis.2.16. LC–MS/MS analysis
The mass spectroscopy (MS) analysis was performed using an
LTQ-Orbitrap XL mass spectrometer (Thermo Scientiﬁc, San Jose, CA,
USA), coupled with online micro ﬂow HPLC system (Shimadzu,
Japan). The concentration of each SCX fraction dissolved in 0.1% FA
was diluted to 0.5 μg/μl. For each sample, 10 μl solution was loaded
onto a 200-μm internal diameter×2-cm-length C18 trap column with
100% Buffer C (2% ACN, 0.1% FA) at 15 μl/min for 10 min, and then the
peptideswere separated using a 75-μm internal diameter×10-cm-length
analytical C18 PicoFrit column. The peptides were eluted at a ﬂow rate of
400 nl/min across the separation column with a linear gradient of 2–35%
Buffer D (98% ACN, 0.1% FA) for 44 min, 35–80% Buffer D for 2 min,main-
tenance in 80%Buffer D for 4 min, and then returning to 2% Buffer Dwith-
in 1 min. The LTQ-Orbitrap XLwas operated in a data-independentmode
automatically switching betweenMS,MS/MS and higher-energy collision
dissociation (HCD) using a threshold of 30,000 for ion selection. ThemassFig. 2. The prognostic signiﬁcance was assessed using Kaplan–Meier survival estimate and l
criterion for immunohistochemistry, Group 1, the patient whose extra part from the score o
the patient whose extra part from the score of the HCC tissue minus that of the para-cancespectrometer data was acquired in the positive ion mode with a selected
mass range of 350–2000 m/z.2.17. Protein identiﬁcation and database search
The data acquisition was performed with Xcalibur 2.1 software
(Thermo Fisher) and the proteins were identiﬁed and quantiﬁed
using Mascot search engine (Matrix Science, London, U.K.; version
2.3.2) with the Mascot Daemon program (Matrix Science; version
2.3.2). The deﬁned parameters were as follows: (1) Type of search,
MS/MS Ion search; (2) Enzyme, Trypsin; (3) Peptide Mass Tolerance,
10 ppm; (4) Fragment Mass Tolerance, ±0.05 Da; (5) Fixed modiﬁca-
tions, Carbamidomethyl (C); (6) Variable modiﬁcations, Gln→pyro-
Glu (N-term Q) and Oxidation (M); (7) Max Missed Cleavages, 1; and
(8) Database, IPI_human, (total sequences, 89,378; total residues,
35,817,989).
The proteins were identiﬁed with at least one unique peptide. Fol-
lowing identiﬁcation, those with a minimum of two unique peptides
were used for further quantiﬁcation analysis. The differentially
expressed proteins were deﬁned as the expression ratio of >1.50 or
b0.67 compared with the control. Furthermore, the differentially
expressed proteins were categorized using Gene Ontology (GO)og-rank test. Comparison of OS (A) and TTR (B) by UCH37 expression. According to the
f the HCC tissue minus that of the para-cancerous tissue was less than 2; and Group 2,
rous tissue was greater than or equal to 2.
Table 3





Female 8 5 0.842
Male 53 24
Age, y
≤52 31 18 0.317
>52 30 11
HBsAg
Negative 4 5 0.229
Positive 57 24
HCV
Negative 61 27 0.101⁎
Positive 0 2
ALT, units/L
≤75 51 26 0.658
>75 10 3
Preoperative AFP, ng/mL
≤20 28 9 0.180
>20 33 20
Liver cirrhosis
No 5 4 0.652
Yes 56 25
BCLC stage
A 11 7 0.499
B/C 50 22
Tumor size
≤5 cm 18 12 0.264
>5 cm 43 17
Tumor number
Single 46 23 0.683
Multiple 15 6
Tumor encapsulation
No 39 21 0.425
Complete 22 8
Vascular invasion
No 36 17 0.972
Yes 25 12
TNM stage
I 30 13 0.699
II–III 31 16
Tumor differentiation
I–II 58 26 0.335
III–IV 3 3
⁎ Fisher's exact tests; χ2 tests for all the other analyses.
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using the Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
ways database [24].
2.18. Statistical analysis
All values were expressed as mean±standard deviation (SD). Sta-
tistical analyses were done by SPSS 16.0 for Windows (SPSS). The χ2
test, Fisher's exact test, and Student's t test were used for comparison
between groups. Cumulative survival time and cumulative recurrence
rate were calculated by the Kaplan–Meier method and analyzed by
the log-rank test. Univariate and multivariate analyses were based on
the Cox proportional hazard regression model. pb0.05 was considered
statistically signiﬁcant.
3. Results
3.1. UCH37 expression in HCC patients and factors associated with
prognosis
Immunostaining for UCH37 was assessed in the cancerous tissues
and the adjacent non-cancerous liver tissues in 90 cases of human
HCC (Fig. 1). The percentage of UCH37 positivity in the cancerous tis-
sues was signiﬁcantly higher than that in the para-cancerous tissues
[92.2% (83/90) vs. 74.4% (67/90), respectively, p=0.001]. Among 61
recurrence patients, we found out the similar result [92.2% (55/61)
positive in HCC vs. 70.5% (43/61) in para-cancerous tissues, respec-
tively, p=0.006]. The paired t test showed that the expression of
UCH37 in the cancerous tissues was signiﬁcantly higher than that in
the adjacent para-cancerous tissues (pb0.001), which was also
found among 61 recurrence patients (pb0.001).
Univariate analysis showed that tumor size, TNM stage and vascu-
lar invasion were unfavorable predictors for OS and TTR. AFP level
and BCLC stage were associated with OS, and encapsulation was asso-
ciated with TTR (Table 1). Meanwhile, UCH37 was found to be prog-
nostic for TTR (p=0.006, Table 1), but not for OS (p=0.08, Table 1,
Fig. 2A). The patient, whose extra part from the score of the HCC tis-
sue minus that of the para-cancerous tissue was greater than or equal
to 2, had a higher cumulative risk of developing HCC recurrence after
resection (Fig. 2B). Multivariate analysis indicated that UCH37 was an
independent prognosticator for TTR (p=0.004, Table 2). However,
UCH37 expression was not related with other clinicopathologic char-
acteristics (Table 3).Table 2
Multivariate analyses of factors associated with OS and TTR.
Hazard ratio (95% CI) p
OSa
BCLC stage (stage B/C vs. A) 2.557 (0.758–8.625) 0.130
AFP, ng/mL (>20 vs. ≤20) 1.968 (1.054–3.675) 0.034
Tumor size, cm (>5 vs. ≤5) 1.567 (0.717–3.424) 0.260
TNM stage (II–III vs. I) 1.292 (0.681–2.449) 0.433
Vascular invasion (yes vs. no) 1.779 (0.973–3.253) 0.062
TTRb
Tumor encapsulation (complete vs. none) 0.616 (0.336–1.126) 0.116
Tumor size, cm (>5 vs. ≤5) 2.072 (1.118–3.841) 0.021
TNM stage (II–III vs. I) 1.326 (0.758–2.319) 0.323
Vascular invasion (yes vs. no) 1.648 (0.960–2.828) 0.070
UCH37HCC–para-HCC (≥2 vs. b2)c 2.449 (1.378–4.351) 0.002
Note: Multivariate analysis and Cox proportional hazards regression model were used.
Variables were adopted for their prognostic signiﬁcance by univariate analysis
(pb0.05).
a BCLC stage, AFP, tumor size, TNM stage and vascular invasion were included in
multivariate analysis for OS.
b Tumor encapsulation, tumor size, TNM stage, vascular invasion and UCH37 expres-
sion were included in multivariate analysis for TTR.
c UCH37HCC–para-HCC: The extra part from the score of the HCC tissue minus that of
the para-cancerous tissue, according to the criterion for immunohistochemistry.3.2. Establishment of stable monoclonal cell lines
To explore the biological roles of UCH37 in HCC, we established
stable monoclonal cell lines by altering the UCH37 expression level.
The treated monoclonal L02 cells stably expressing the Flag–UCH37
fusion protein were performed (Fig. 3A, C). Meanwhile, we infected
a retrovirus-expressing shRNA speciﬁc to UCH37 into Huh7 cells
and generated stable monoclonal UCH37-knockdown Huh7 cells
(Fig. 3B, D).
3.3. UCH37 does not affect cell apoptosis and cell cycle distribution in
HCC cells
To evaluate the effect on apoptosis of UCH37 in HCC cells, the pres-
ence of apoptotic cells was determined by the application of double
staining with FITC-Annexin V and PI. Early apoptotic cells were repre-
sented as FITC-positive and PI-negative, and late apoptotic cells as
FITC-positive and PI-positive. Consequently, no signiﬁcant difference
was found in the apoptotic cell fraction between the UCH37
overexpressing/silencing cells and the control cells (Fig. 4A, B). We also
analyzed the cell cycle distribution of the stable cell lines by ﬂow cytom-
etry after PI staining. The results showed that the cell cycle
Fig. 3. Establishment of stable monoclonal cell lines. The mRNA level of UCH37 was assessed in the treated L02 (A) or Huh7 (B) cells. Real-time PCR of β-actin mRNA expression was
performed as a control. Data were presented as mean value±standard deviation (SD). * pb0.05, *** pb0.001. The protein level of UCH37 was assessed in the treated L02 (C) or Huh7
(D) cells. GAPDH was used as a loading control. L02-pLenti6.3, L02 cells carrying an empty vector; L02-UCH37, the monoclonal L02 cells stably expressing Flag-UCH37 fusion pro-
tein; Huh7-pLKO.1, Huh7 cells carrying an empty vector; and Huh7-shUCH37, the stable monoclonal Huh7 cells whose UCH37 expression was down-regulated.
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UCH37 overexpressing/silencing cells, compared with the control cells
(Fig. 4C, D).
3.4. UCH37 promotes cell migration and invasion
Since metastasis and recurrence represent the main deleterious
characteristic of HCC,we determined themigratory and invasive poten-
tial of the treated cell lines. In the scratch assay, the treated L02 cells sta-
bly expressing the Flag–UCH37 fusion protein migrated into the wound
area and organized a dense cellular network, resulting in nearly com-
plete wound recovery after 48 h, while migration into the wound area
of Huh7-shUCH37 cells was signiﬁcantly inhibited (Fig. 5A, B).
In the transwell migration assay, the migrated cells increased from
98±10 cells per ﬁeld for control to 183±16 cells per ﬁeld for
L02-UCH37 cells (pb0.01) (Fig. 5C). The migrated cells in control
cells and Huh7-shUCH37 cells were, respectively, 97±4 cells and
28±4 cells (pb0.001) (Fig. 5D). In the transwell invasion assay, we
found out the similar results. UCH37-knockdown reduced the cell ca-
pability to invade extracellular matrix (Huh7-pLKO.1, 23±3 vs.
Huh7-shUCH37, 3±1, pb0.05), whereas forced expression of UCH37
increased invasiveness (L02-pLenti6.3, 14±2 vs. L02-UCH37, 51±2,
pb0.001) (Fig. 5E, F). These data indicated that UCH37 promoted mi-
gratory and invasive abilities in vitro, and demonstrated that reducing
UCH37 expression level attenuated HCC cell aggressiveness.
3.5. Identiﬁcation of differentially expressed proteins using iTRAQ
To determine differentially expressed proteins that may serve as
potential interaction targets of UCH37, total proteins, extracted from
the treated L02 cells stably expressing the Flag–UCH37 fusion protein
and the L02 cells carrying an empty vector, were analyzed using
iTRAQ experiments. In total, 2134 proteins (7225 unique peptides)
were conﬁdently identiﬁed, of which 1680 proteins were used forfurther quantiﬁcation analysis. Using the criteria described in the
“Material and methods”, 19 proteins were found to be up-regulated
and 21 down-regulated in the treated L02 cells, compared with the
control cells (Table 4).
3.6. Functional classiﬁcation and pathway analysis of differentially
expressed proteins
In order to understand the biological impact of UCH37, the differ-
entially expressed proteins identiﬁed by iTRAQ were imported into
the Gene Ontology (GO) database (http://www.geneontology.org/)
and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways
database. For GO analysis, the proteins were categorized based on cel-
lular component, molecular function or biological process. As a result,
the proteins appeared to be distributed all over the cell (Supplemen-
tary Table 2). The top six molecular functions included protein
binding, catalytic activity, nucleic acid binding, transcription regula-
tor activity, enzyme regulator activity and transferase activity (Sup-
plementary Table 3). In addition, the proteins were found to
participate in a variety of important biological processes including
metabolic, immune, response to stimulus, cellular, and transport-
related processes (Supplementary Table 4). For KEGG pathways
analysis, the proteins covered 55 KEGG pathways, including
spliceosome, focal adhesion, metabolism, endocytosis, antigen pro-
cessing and presentation, MAPK signaling pathway, TGF-β signaling
pathway and Wnt signaling pathway (Supplementary Tables 5–7).
3.7. UCH37 deubiquitinates PRP19 and interacts with PRP19
We selected some of the up-regulated proteins for immunoblot
analysis (Supplementary Fig. 2). Although the direction of the change
as detected by iTRAQ was consistent with the immunoblot analysis,
there was some degree of difference between the two techniques.
These differences observed between the two techniques could be
Fig. 4. UCH37 does not affect cell apoptosis and cell cycle distribution in HCC cells. Cell apoptosis was assessed by double staining of FITC-AnnexinV/PI and subsequently ﬂow
cytometry (A and B). The patterns shown are representative of three separate experiments (left and middle). The percentages of early apoptotic cells and late apoptotic cells
were counted (right). Cell cycle distribution was analyzed by ﬂow cytometry after PI staining (C and D). The patterns shown are representative of three separate experiments
(left and middle). The percentages of cells in each phase were counted (right). Columns represented the mean of three independent experiments; bars, SD; L02-pLenti6.3, L02
cells carrying an empty vector; L02-UCH37, the monoclonal L02 cells stably expressing Flag-UCH37 fusion protein; Huh7-pLKO.1, Huh7 cells carrying an empty vector; and
Huh7-shUCH37, the stable monoclonal UCH37-knockdown Huh7 cells.
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herent in each technical approach, and/or some other uncertainties.
Consequently, PRP19 was chosen for further study, because PRP19
was consistently signiﬁcantly up-regulated in L02-UCH37 cells com-
pared with the control cells using both techniques.
Although the protein level of PRP19 was increased in L02-UCH37
cells, compared with the control cells (Fig. 6A), the mRNA level of
PRP19 presented no signiﬁcant difference between the two cells(Fig. 6B). To investigate whether the degradation of PRP19 was medi-
ated through ubiquitin proteasome pathway (UPP), L02 cells were
treated with proteasome inhibitor MG132 (10 μmol/L) for 24 h. Our
results indicated that the addition of MG132 induced accumulation
of PRP19 (Fig. 6C). Furthermore, to investigate whether PRP19 was
one of UCH37 substrates, the level of ubiquitinated PRP19 was
assessed. Co-immunoprecipitation (co-IP) assay indicated that when
the expression of PRP19 was the same in both cells, the level of
Fig. 5. UCH37 promotes cell migration and invasion. (A and B) Representative images at 48 h after wounding were shown. (C and D) Cells were seeded in the top chamber with a
non-coated membrane and allowed to migrate for 48 h. (E and F) Cells were seeded in the top chamber with a Matrigel-coated membrane and allowed to invade for 48 h. Migrated
or invaded cells were stained by crystal violet. Representative images of three independent experiments were shown. The magniﬁcation was 100 (C) and 200 (A, B, D, E and F). (G)
The number of migrated or invaded cells was manually counted in four independent ﬁelds per well with light microscope. Columns represented the average of four random ﬁelds;
bars, SD; L02-pLenti6.3, L02 cells carrying an empty vector; L02-UCH37, the monoclonal L02 cells stably expressing Flag-UCH37 fusion protein; Huh7-pLKO.1, Huh7 cells carrying an
empty vector; Huh7-shUCH37, the stable monoclonal UCH37-knockdown Huh7 cells. * pb0.05, ** pb0.01, *** pb0.001.
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compared with the control cells (Fig. 6D).
However, immunoblot analysis showed that the expression of
PRP19 did not present any signiﬁcant change in the monoclonal
UCH37-knockdown Huh7 cells, compared with Huh7 cells carrying
an empty vector (Fig. 6E). Then, the expression of PRP19 from the
control cells and Huh7-shUCH37 cells treated with 20 μM cyclohexi-
mide for different time intervals was analyzed by western blotting.
The results showed that the silencing of UCH37 revealed an increased
rate of degradation of PRP19, indicating the physiological relevance of
UCH37 in regulating PRP19 (Fig. 6F).
Subsequently, the possibility that UCH37 could interact with PRP19
was conﬁrmed by co-IP and confocal laser scanning microscopy analy-
sis. Consequently, in L02-UCH37 cells, PRP19 was easy to be de-
tected through anti-PRP19 antibody in the Flag-immunoprecipitates
(Fig. 7A). Reciprocal co-IP experiments using anti-PRP19 antibody indi-
cated the existence of Flag and UCH37, as conﬁrmed by immuno-
blotting (Fig. 7B). To verify the stringency of co-IP, parallel
experiments were done in which co-IP antibody was replaced
with isotype control antibody or PBS. Meanwhile, control ex-
periments showed that PRP19 was exactly associated with UCH37,but not with Flag (Supplementary Fig. 3). This interaction of UCH37
with PRP19 with endogenously UCH37 was conﬁrmed in Huh7 cells
(Fig. 7C, D).
Furthermore, the localizations of UCH37 and PRP19 were visual-
ized under confocal laser scanning microscopy. The L02-UCH37 cells
expressing the Flag–UCH37 fusion protein exhibited ﬂuorescence
concentrated in the cytoplasm, and also in the nucleus. PRP19 was
found to be mainly localized in the nucleus. Co-localization of two
proteins in the nucleus was evidenced by overlapping ﬂuorescence
signals (Fig. 7E, F). While in the Huh7 cells, the distribution of
PRP19 was diffuse — nucleus and cytoplasm as did UCH37.
Overlapping ﬂuorescence signals showed that two proteins were
co-localized mainly in the nucleus, and also a little in the cytoplasm
(Fig. 7G).
3.8. PRP19 is involved in UCH37-induced HCC cell migration and
invasion
To investigate the relationship between UCH37, PRP19 and the ca-
pability of cell migration and invasion, the expression of PRP19 in
L02-UCH37 cells was down-regulated by siRNA (Fig. 8A). Intriguingly,
Table 4
The differentially expressed proteins between the monoclonal L02 cells stably expressed the Flag-UCH37 fusion protein and the L02 cells carrying an empty vector.
Prot_acc Prot_desc Ratio (UCH37/Control)
IPI00935516 Tax_Id=9606 Gene_Symbol=HSBP1 Heat shock factor-binding protein 1 1717.797
IPI00018963 Tax_Id=9606 Gene_Symbol=PARVA Isoform 1 of Alpha-parvin 1717.797
IPI00060523 Tax_Id=9606 Gene_Symbol=TLCD1 TLC domain-containing protein 1 3.081
IPI00299313 Tax_Id=9606 Gene_Symbol=UCHL5 Isoform 1 of Ubiquitin carboxyl-terminal hydrolase isozyme L5 2.619
IPI00220528 Tax_Id=9606 Gene_Symbol=SNRPF Small nuclear ribonucleoprotein F 2.489
IPI00025344 Tax_Id=9606 Gene_Symbol=NDUFS6 NADH dehydrogenase [ubiquinone] iron–sulfur protein 6, mitochondrial 2.394
IPI00873472 Tax_Id=9606 Gene_Symbol=SEC24A Isoform 1 of Protein transport protein Sec24A 2.236
IPI00004968 Tax_Id=9606 Gene_Symbol=PRPF19 Pre-mRNA-processing factor 19 1.999
IPI00005793 Tax_Id=9606 Gene_Symbol=AP3B2 AP-3 complex subunit beta-2 1.953
IPI00554723 Tax_Id=9606 Gene_Symbol=SNORA70; RPL10 60S ribosomal protein L10 1.807
IPI00037283 Tax_Id=9606 Gene_Symbol=DNM1L Isoform 5 of Dynamin-1-like protein 1.775
IPI00299468 Tax_Id=9606 Gene_Symbol=SCD Acyl-CoA desaturase 1.738
IPI00470779 Tax_Id=9606 Gene_Symbol=TXLNA Alpha-taxilin 1.678
IPI00030362 Tax_Id=9606 Gene_Symbol=PLP2 Proteolipid protein 2 1.597
IPI00062599 Tax_Id=9606 Gene_Symbol=−71 kDa protein 1.559
IPI00009922 Tax_Id=9606 Gene_Symbol=C14orf156 SRA stem-loop-interacting RNA-binding protein, mitochondrial 1.526
IPI00304925 Tax_Id=9606 Gene_Symbol=HSPA1B; HSPA1A Heat shock 70 kDa protein 1A/1B 1.517
IPI00015560 Tax_Id=9606 Gene_Symbol=ELP2 Isoform 1 of Elongator complex protein 2 1.502
IPI00306127 Tax_Id=9606 Gene_Symbol=THUMPD3 THUMP domain-containing protein 3 1.502
IPI00412713 Tax_Id=9606 Gene_Symbol=SAMM50 Sorting and assembly machinery component 50 homolog 0.662
IPI00023344 Tax_Id=9606 Gene_Symbol=SYMPK Isoform 1 of Symplekin 0.656
IPI00005715 Tax_Id=9606 Gene_Symbol=UBE4B Isoform 1 of Ubiquitin conjugation factor E4 B 0.656
IPI00027681 Tax_Id=9606 Gene_Symbol=NNMT Nicotinamide N-methyltransferase 0.653
IPI00384872 Tax_Id=9606 Gene_Symbol=UGT1A7 UDP-glucuronosyltransferase 1-7 0.642
IPI00010863 Tax_Id=9606 Gene_Symbol=ATOX1 Copper transport protein ATOX1 0.637
IPI00219673 Tax_Id=9606 Gene_Symbol=GSTK1 Glutathione S-transferase kappa 1 0.63
IPI00006702 Tax_Id=9606 Gene_Symbol=PELP1 cDNA FLJ56414, highly similar to Homo sapiens proline-, glutamic acid-, leucine-rich
protein 1 (PELP1), mRNA
0.622
IPI00021347 Tax_Id=9606 Gene_Symbol=UBE2L3 Ubiquitin-conjugating enzyme E2 L3 0.609
IPI00007423 Tax_Id=9606 Gene_Symbol=ANP32B Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family member B 0.603
IPI00025815 Tax_Id=9606 Gene_Symbol=TARDBP TDP43 0.6
IPI00154975 Tax_Id=9606 Gene_Symbol=DNAJC9 DnaJ homolog subfamily C member 9 0.593
IPI00293350 Tax_Id=9606 Gene_Symbol=TSNAX Translin-associated protein X 0.574
IPI00293276 Tax_Id=9606 Gene_Symbol=MIF Macrophage migration inhibitory factor 0.563
IPI00218658 Tax_Id=9606 Gene_Symbol=ITPR1 Isoform 2 of Inositol 1,4,5-trisphosphate receptor type 1 0.553
IPI00158615 Tax_Id=9606 Gene_Symbol=THOC2 THO complex subunit 2 0.537
IPI00013160 Tax_Id=9606 Gene_Symbol=LGTN Isoform 1 of Ligatin 0.513
IPI00064767 Tax_Id=9606 Gene_Symbol=ARHGAP17 Isoform 1 of Rho GTPase-activating protein 17 0.492
IPI00019517 Tax_Id=9606 Gene_Symbol=WT1 Isoform 1 of Wilms tumor protein 0.41
IPI00744711 Tax_Id=9606 Gene_Symbol=PNPT1 Polyribonucleotide nucleotidyltransferase 1, mitochondrial 0.399
IPI00301489 Tax_Id=9606 Gene_Symbol=UROD Uroporphyrinogen decarboxylase 0.002
Prot_acc, protein accession number; Prot_desc, protein description; UCH37, the monoclonal L02 cells stably expressed the Flag-UCH37 fusion protein; and control, the L02 cells
carrying an empty vector.
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with PRP19 siRNA were signiﬁcantly weakened (Fig. 8B–D). This ﬁnd-
ing was conﬁrmed with two other independent PRP19 siRNA
oligoribonucleotides (Supplementary Figs. 4, 5).4. Discussion
Hepatocellular carcinoma (HCC) represents one of the most chal-
lenging cancers [25]. Ubiquitin C-terminal hydrolase 37 (UCH37) is a
member of the ubiquitin C-terminal hydrolase (UCH) which is a sub-
family of deubiquitinating enzymes (DUBs) [26–28]. Previous studies
have shown its potential roles in oncogenesis. Rolén U et al. have
found that the activity of the C-terminal hydrolases UCH37 is
up-regulated in the majority of tumor tissues compared with the adja-
cent normal tissues [29]. Kapuria V et al. have found that WP1130, a
partly selective DUB inhibitor which directly inhibits DUB activity of
USP5, USP9x, USP14 and UCH37, could mediate inhibition of
tumor-activated DUBs resulting in down-regulation of anti-apoptotic
and up-regulation of proapoptotic proteins [30]. Chen Y and his col-
leagues have showed that the protein expression level of UCH37 was
higher in the esophageal squamous cell carcinoma (ESCC) tissues
than in para-tumorous tissues and that UCH37 was overexpressed in
the tumor tissues of recurrence patients [31].Here, we provided evidence for the ﬁrst time that the HCC cancer-
ous tissues had higher UCH37 expression relative to the adjacent
para-cancerous tissues, which further conﬁrmed the previous re-
searches. The result of multivariate analysis also showed us that
UCH37 could be a predictor for the time to recurrence (TTR) and
had the potential power to predict the HCC recurrence after curative
resection. Although some recognized factors, such as BCLC stage,
TNM stage, encapsulation and vascular invasion were associated
with overall survival (OS) and/or TTR in univariate analysis, they
presented no statistical signiﬁcance in multivariate analysis, most
likely because of the limited number of patients enrolled in this
study. Therefore, further investigation with a large-scale and longer
follow-up study should be required to conﬁrm its potential role in
HCC recurrence.
As mentioned in the Introduction, previous work has showed that
UCH37 possesses deubiquitinating activity via associating with the
proteasome or hINO80. Some literature has also reported the biological
roles and interactant of UCH37. The interaction between Smads and
UCH37 could potentially counteract Smurf-mediated ubiquitination.
UCH37 competes with Smurf2 in binding concurrently to Smad7 so
that it deubiquitinates the activated type I TGF-β receptor, thereby res-
cuing it from proteasomal degradation. The up-regulation of TGF-β sig-
naling by UCH37 could also be partly explained by the deubiquitination
and stabilization of Smad3 [32,33]. UCH37 knockdown signiﬁcantly
Fig. 6. UCH37 deubiquitinates PRP19. (A) Over-expression of UCH37 up-regulated PRP19. GAPDH was used as a loading control. (B) The mRNA level of PRP19 was assessed in the
control cells and the treated L02 cells. Real-time PCR of β-actin mRNA expression was performed as a control. Data were presented as mean value±SD. (C) The degradation of
PRP19 was mediated through ubiquitin proteasome pathway. L02, L02 cells; MG132, L02 cells were treated in presence of MG132 (10 μmol/L) for 24 h. GAPDH was used as a load-
ing control. (D) UCH37 deubiquitinated PRP19. For co-IP experiments using anti-Ub antibody, the level of PRP19 in the treated L02 cells was the same as that in the control cells.
L02-pLenti6.3, L02 cells carrying an empty vector; L02-UCH37, the monoclonal L02 cells stably expressing Flag-UCH37 fusion protein. (E) The protein level of PRP19 was assessed in
the control cells and Huh7-shUCH37 cells. GAPDH was used as a loading control. (F) PRP19 proteins from the control cells and Huh7-shUCH37 cells treated with 20 μM cyclohex-
imide for different time intervals were analyzed by western blotting. Huh7-pLKO.1/control, Huh7 cells carrying an empty vector; Huh7-shUCH37/shUCH37, the stable monoclonal
Huh7 cells whose UCH37 expression was down-regulated.
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decreases levels of some TGF-β-dependent target genes, notably p21, a
proteinwhich plays a key role in cell cycle arrest by preventingG1/S cell
cycle progression and inhibits proliferation, and PAI-1, a scaffold protein
that has been shown to act as a tumor suppressor and induce apoptosis
via caspase-3, during the early phase of TGF-β receptor activation. Yet
UCH37 knockdown signiﬁcantly impairs cell migration in pancreatic
cancer cell lines through the abolition of the TGF-β-induced expression
of MMP-2 and PAI-1, which are thought to play a key role in TGF-
β-dependent cell migration and tumor invasion, at both early and late
stages of TGF-β receptor activation [34]. Chen Z et al. have showed
that the ratio of Bax/Bcl-2 is higher in silencing of UCH37 than in that
of control group after that of UCH37 in A549 cells. Meanwhile, experi-
ments with the A549 cell line disclose that silencing of UCH37 could in-
duce efﬁciently A549 cell apoptosis through activation of caspase-9 and
caspase-3. On the other hand, over-expression of UCH37 leads to the
opposite effect [35]. Recently, our group have showed that the quantity
of UCH37 rises in HCC using a functional proteomic analysis to screen
UCH37-interacting proteins in HCC, thus identifying glucose-regulated
protein 78 (GRP78), essential for cell viability, as one interacting with
UCH37 [36]. All of the evidences suggest that the up-regulation of
UCH37 may play an important role in oncogenesis through promotingsome proto-oncogenes' expression and stem cell-like characteristics in
the cell.
In our study, UCH37 was found to promote cell migration and inva-
sion in HCC cells in vitro, which was consistent with the results of im-
munohistochemistry in our clinical research. To better understand the
effect of UCH37 on quantitative protein changes in HCC, we utilized
the differential proteomics which is Isobaric Tag for Relative and Abso-
lute Quantitation (iTRAQ) in combination with LC–MS/MS. iTRAQ has
gained popularity for its ability to perform concurrent identiﬁcation
and relative quantiﬁcation of hundreds of proteins [37–40], and has
been employed in several oncoproteomics studies [41–44]. iTRAQ data
showed that the differentially expressed proteins (19 up-regulated
and 21 down-regulated) were widely distributed in the cell, and dem-
onstrated that they played a role in all aspects of cell biology, indicating
that UCH37 were involved in almost all biological processes.
As mentioned above, PRP19 was chosen for further study. PRP19, a
core component of the spliceosomal NineTeen associated-Complex
(NTC) [45,46], plays a direct role in the activation and structural sta-
bilization of the spliceosome [47–50]. Previous studies have indicated
that PRP19 complex is associated with tumorigenesis. It is a tempting
hypothesis that aberrant splicing results in inaccurate sister chroma-
tid segregation, thereby leading to tumorigenesis [51,52]. On the
Fig. 7. UCH37 interacts with PRP19. (A) The cell lysates from L02-UCH37 cells were co-immunoprecipitated with anti-Flag antibody and immunoblotted with anti-Flag and
anti-PRP19 antibodies, respectively. Lane 1, Flag-immunoprecipitates from L02-UCH37 cells; lane 2, the cell lysates from L02-UCH37 cells co-immunoprecipitated with isotype con-
trol antibody; lane 3, the cell lysates from L02-UCH37 cells co-immunoprecipitated with PBS. (B) The cell lysates from L02-UCH37 cells were co-immunoprecipitated with
anti-PRP19 antibody and immunoblotted with anti-PRP19, anti-Flag and anti-UCH37 antibodies, respectively. Lane 1, PRP19-immunoprecipitates from L02-UCH37 cells; lane 2,
the cell lysates from L02-UCH37 cells co-immunoprecipitated with isotype control antibody; lane 3, the cell lysates from L02-UCH37 cells co-immunoprecipitated with PBS.
(C and D) The interaction of UCH37 with PRP19 with endogenously UCH37 was conﬁrmed in Huh7 cells via co-immunoprecipitation. (E and F) Co-localization of Flag-UCH37 fusion
protein and PRP19 was examined by confocal laser scanning microscopy analysis in L02-UCH37 cells. (G) Co-localization of UCH37 with PRP19 with endogenously UCH37 was ex-
amined by confocal laser scanning microscopy analysis in Huh7 cells. A merged image was illustrated by yellow signal and nuclei were visualized by DAPI. The magniﬁcation was
945 (E and F) and 1890 (G), and the length of the scale bar was 20 μm.
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ing of DNA lesions particularly DNA interstrand cross-links (ICLs)
[53–55]. It has been previously reported that over-expression of
PRP19 complex increases cellular lifespan in human cells possibly
by enhancing DNA repair capacity [56]. Otherwise, PRP19 complex
has been recently found to be involved in DNA damage checkpoint
signaling pathways [57]. Thus, PRP19 complex functions in two as-
pects of the DNA damage response (DDR), namely DNA repair and
checkpoint signaling.
In the current study,weobserved that the deubiquitination of PRP19
was regulated by UCH37. Furthermore, PRP19 was identiﬁed as one of
UCH37-interacting proteins, which was conﬁrmed by co-IP and confo-
cal laser scanning microscopy analysis (both over-expressed and en-
dogenous). To determine the relationship between UCH37, PRP19 and
the capability of cell migration and invasion, the expression of PRP19
in L02-UCH37 cells was down-regulated by siRNA. Intriguingly,
knock-down of PRP19 reduced the capability of cellmigration and inva-
sion, compare with the control cells, suggesting that UCH37 exerted its
effects at least in part by deubiquitinating and stabilizing PRP19.
Taken together, the results of this study demonstrated that UCH37
could promote cell migration and invasion in HCC cell lines through
interacting and deubiquitinating PRP19. Furthermore, it is in HCC
that we ﬁrst reported UCH37 could be a predictive marker of HCC re-
currence after curative resection. We believe that UCH37 could be agood diagnostic and therapeutic target for controlling HCC recur-
rence, and further investigations in this ﬁeld are needed.
5. Conclusion
This study provided evidence for the ﬁrst time that UCH37 could
promote cell migration and invasion in HCC cell lines through
interacting and deubiquitinating PRP19, and this is the ﬁrst report
showing UCH37 as a predictive marker of HCC recurrence in HCC pa-
tients after curative resection.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.11.020.
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